testis expressed metallothionein like proteinGenealiases: CXCDC2 · MTL5 · MTLT
Q-omics provides the consensus-scored TESMIN profile across patient tissues and cancer cell-line models. TESMIN expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TESMIN is differentially expressed in 17, with the highest sampling consensus in LUAD. Additionally, TESMIN RNA expression shows 19,070 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, and ACC as cancer lineages where TESMIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TESMIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TESMIN survival associations across molecular data types. TESMIN RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TESMIN RNA expression–survival associations across cancer types. High TESMIN expression shows unfavorable associations in LUAD, UVM, UCEC, LIHC and CESC, but favorable associations in READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TESMIN RNA expression.
This table summarizes TESMIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TESMIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TESMIN shows lower tumor expression in KIRC and higher tumor expression in LUAD, COAD, LUSC, STAD and BLCA. The LUAD box plot shows higher TESMIN RNA expression in tumor versus normal tissue (log2 FC = +2.545, t-test p < 0.001).
This table shows molecular features associated with TESMIN in patient tissues and cancer cell lines. In patient samples, TESMIN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TESMIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
